Next Generation Gene Therapy Vectors

The inaugural Next Generation Gene Therapy Vectors meeting is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.

Industry pioneers from cutting edge biotechs and world-leading academic vectorology groups including Dyno Therapeutics, 4D Molecular Therapeutics and Generation Bio will share how ever-increasing clinical experience is guiding strategies to decrease the immunogenicity of vectors to allow durable transgene expression, engineer vectors with lower toxicity at higher doses and use innovative technologies to optimise capsid, transgene, and promoter design.

Everything in gene therapy starts with the vector, so join this definitive, niche, digital conference to delve into the details of vector design, engineering, and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.

Prices:
Conference + 2 Workshops - Standard: USD 2797.00,
Conference + 1 Workshop - Standard: USD 2398.00,
Conference Only - Standard: USD 1999.00,
Conference + 2 Workshops - Academic and Non-Profit: USD 2397.00,
Conference + 1 Workshop - Academic and Non-Profit: USD 2098.00,
Conference Only - Academic and Non-Profit: USD 1799.00

Speakers: Leah Byrne, Assistant Professor of Ophthalmology, University of Pittsburgh, Nelson Chau, VP, Discovery Biology and Translational Research, LogicBio, Vivian Choi, Head of Global Gene Therapy Research, Takeda, Casey Case, Founder, Eleutheria, Dirk Grimm, Professor, University of Heidelberg, Nachi Gupta, Chief Technology Innovation Officer, Kriya Therapeutics, Matthias Hebben, VP, Technology Development, LogicBio, Eric Kelsic, CEO, Dyno Therapeutics, Robert Kotin, Adjunct Professor, University of Massachusetts, Melissa Kotterman, Co-Founder; Vice President, Discovery and Engineering, 4D Molecular Therapeutics, Ye Liu Senior, Director, Gene Transfer Technology, R and D, REGENXBIO, Abraham Scaria, CSO, IVERIC Bio, Charles Shyng, Principal Scientist, AAV, Rare Disease, Pfizer, Lawrence Tam, Group Lead, Vector Engineering, Gyroscope Therapeutics, Genine Winslow, CEO, Chameleon Biosciences, Zhong Zhong, VP, Gene Therapy, Generation Bio, Nicole Paulk, Assistant Professor, Biochemistry and Biophyiscs, University of California San Francisco, Hemant Khanna, Associate Professor, University of Massachusetts Medical School, Russell Monds, Director, Molecular Biology, Generation Bio

Others Details

Brochure: https://go.evvnt.com/729093-3?pid=6581 Time: 08:00 to 16:00